<DOC>
	<DOCNO>NCT01378117</DOCNO>
	<brief_summary>High blood glucose level hospitalize patient diabetes associate increased risk medical complication death . Improved glucose control insulin injection may improve clinical outcome prevent hospital complication . Glargine ( Lantus® ) insulin injection common treatment diabetes hospital . Sitagliptin ( Januvia® ) effective lower blood glucose , test hospital . It known sitagliptin effective control blood sugar hospital . This study compare sitagliptin mouth , insulin ( glargine ) injection , combination sitagliptin lantus insulin control blood sugar hospitalize patient diabetes . In pilot study , patient know history diabetes treat diet and/or OAD low total daily dose insulin therapy ( &lt; 0.4 unit/kg/day ) randomize receive sitagliptin daily ( group 1 ) , sitagliptin plus basal ( glargine ) insulin daily ( group 2 ) , basal bolus regimen glargine daily lispro insulin meal ( group 3 ) . If need , patient 3 treatment group receive correction dose rapid-acting lispro ( Humalog® ) insulin presence hyperglycemia ( BG &gt; 140 mg/dl ) per slide scale . The overall hypothesis treatment sitagliptin daily alone combination basal insulin patient type 2 diabetes result similar improvement glycemic control lower frequency hypoglycemic event treatment basal bolus insulin regimen glargine daily lispro insulin meal . A total 90 subject type 2 diabetes recruit study . Patients recruit Grady Memorial Hospital Emory University Hospital .</brief_summary>
	<brief_title>DPP4 Inhibitor Hospital</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>1 . Males female age 18 80 year admit general medicine surgery service . 2 . A known history T2DM &gt; 3 month , receive either diet alone , oral antidiabetic agent : sulfonylurea metformin monotherapy combination therapy ( exclude TZDs DPP4 inhibitor ) , lowdose ( ≤ 0.4 units/kg/day ) insulin therapy . 3 . Subjects BG &gt; 140 mg &lt; 400 mg/dL without laboratory evidence diabetic ketoacidosis ( serum bicarbonate &lt; 18 mEq/L positive serum urinary ketone ) . 1 . Age &lt; 18 &gt; 80 year . 2 . Subjects increase blood glucose concentration , without know history diabetes ( stress hyperglycemia ) . 3 . Subjects history type 1 diabetes ( suggest BMI &lt; 25 require insulin therapy history diabetic ketoacidosis hyperosmolar hyperglycemic state , ketonuria ) [ 46 ] . 4 . History TZD treatment ( pioglitazone rosiglitazone ) DPP4 inhibitor ( sitagliptin saxagliptin ) past 3 month prior admission . 5 . Acute critical illness CABG surgery expect require prolonged admission critical care unit ( ICU , CCU , SICU , neuro ICU ) . 6 . Subjects gastrointestinal obstruction adynamic ileus expect require gastrointestinal suction . 7 . Medical surgical patient expect kept NPO &gt; 2448 hour admission completion surgical procedure . 8 . Patients clinically relevant pancreatic gallbladder disease . 9 . Patients congestive heart failure ( NYHA class III IV ) , acute myocardial infarction , clinically significant hepatic disease significantly impair renal function ( serum creatinine ≥ 2.0 mg/dL ) . 10 . Treatment oral injectable corticosteroid . 11 . Mental condition render subject unable understand nature , scope , possible consequence study . 12 . Female subject pregnant breast feeding time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>diabetes</keyword>
	<keyword>non critical care set</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>treatment</keyword>
	<keyword>oral antidiabetic agent</keyword>
	<keyword>subcutaneous insulin</keyword>
</DOC>